PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective

Autor: Wenru Song, Delong Liu, Ruirong Yuan, Jun Wang, Zihai Li, Jingwei Sun
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Oncology
PD-L1
Cancer Research
medicine.medical_specialty
CD28
medicine.medical_treatment
Programmed Cell Death 1 Receptor
Awards and Prizes
T cells
Review
lcsh:RC254-282
B7-H1 Antigen
Immunomodulation
03 medical and health sciences
0302 clinical medicine
Cancer immunotherapy
Internal medicine
Neoplasms
PD-1
Medicine
Molecular Biology
immuno-oncology
immune checkpoint
Chinese americans
biology
business.industry
lcsh:RC633-647.5
Cancer
Hematology
Immunotherapy
lcsh:Diseases of the blood and blood-forming organs
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Immune checkpoint
tumor-site immune modulation therapy
3. Good health
B7-H1
030104 developmental biology
CTLA-4
030220 oncology & carcinogenesis
Immunology
biology.protein
immunotherapy
business
Zdroj: Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-8 (2017)
Journal of Hematology & Oncology
ISSN: 1756-8722
DOI: 10.1186/s13045-017-0403-5
Popis: The current success of targeted inhibition against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Death 1/Programmed Death Ligand 1 (PD-1/PD-L1, herein collectively referred to as PD) pathways is hailed as a cancer immunotherapy breakthrough. PD-L1, known also as B7 homolog 1 (B7-H1), was initially discovered by Dr. Lieping Chen in 1999. To recognize the seminal contributions by Chen to the development of PD-directed therapy against cancer, the Chinese American Hematologist and Oncologist Network (CAHON) decided to honor him with its inaugural Lifetime Achievement Award in Hematology and Oncology at the CAHON’s 2015 annual meeting. This essay chronicles the important discoveries made by Chen in the exciting field of immuno-oncology, which goes beyond his original fateful finding. It also argues that PD-directed therapy should be appropriately considered as Tumor-Site Immune Modulation Therapy to distinguish it from CTLA-4-based immune checkpoint blocking agents.
Databáze: OpenAIRE
Externí odkaz: